InBios' Lyme Detect™ Multiplex ELISA Demonstrates Potential to Streamline Lyme Disease Testing in New UConn Health Study

A UConn Health study found InBios International's Lyme Detect Multiplex ELISA achieved 99.2% concordance with standard two-tier Lyme testing while combining screening and confirmation into a single assay. The approach could reduce laboratory turnaround time by more than two hours and potentially replace conventional tiered algorithms, contingent on future FDA regulatory clearance. The findings are positive for InBios' diagnostic-testing pipeline but are early-stage and not yet associated with an FDA-cleared commercial product.

Analysis

This is not investable public-equity news at present: InBios is private, the assay remains research-use-only, and the cited performance metric is concordance versus an existing algorithm rather than prospective clinical-outcome superiority. The relevant gating item is FDA clearance, which can require additional evidence across disease stage, geography, cross-reactivity and intended-use populations; the commercial timeline is therefore more likely measured in quarters than days.

If cleared, the economic value accrues primarily to laboratories through lower hands-on labor, faster sample throughput and reduced send-out complexity—not necessarily to the test developer alone. Large reference labs Quest Diagnostics (DGX) and Labcorp (LH) could eventually benefit from workflow efficiency, but their Lyme revenue exposure is too small for this to move estimates absent broad reimbursement adoption. Conversely, incumbent assay and immunoblot suppliers could face localized pricing pressure, though diversified diagnostics franchises such as Danaher (DHR), Roche (ROG SW), Abbott (ABT) and bioMerieux (BIM FP) have insufficient disclosed Lyme exposure for a directional trade.

The contrarian read is that a two-hour laboratory turnaround improvement does not automatically change patient management: empiric treatment often precedes serology in clinically apparent cases, while serology has known limitations early in infection. Payer coverage, laboratory-information-system integration, and whether a one-step test preserves specificity in low-prevalence settings will determine adoption. A false-positive signal or FDA request for a larger pivotal dataset would materially delay commercialization and undermine the replacement narrative.

Near term, monitor FDA submission/clearance, CPT coding or payer-policy changes, and any disclosed placement agreement with DGX, LH, hospital networks, or state public-health laboratories. Without those milestones or a public vehicle through which to own InBios, this is a watch item rather than a trade catalyst.

Key Decisions for Investors

• No directional position based solely on this release; private-company exposure and pre-clearance status make the signal non-actionable for liquid public markets.
• Create an event alert for FDA clearance or a named national-reference-lab commercialization agreement; reassess DGX and LH only if adoption economics or test-volume contribution are disclosed.
• For diagnostics holdings, treat any Lyme-specific competitive concern for DHR, ABT, ROG SW or BIM FP as immaterial unless management identifies revenue exposure or broad tick-borne multiplex adoption; do not short diversified incumbents on this basis.
• Watch reimbursement and clinical-guideline developments over the next 6-18 months. A favorable coverage decision plus validated real-world specificity would be the required confirmation that workflow savings can translate into durable pricing and utilization.